SCHEMBL11908142

SCHEMBL11908142

CCOc1ccc(F)c(-c2ccc(N)c(C(=O)O)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.49
FFAR4 Q5NUL3 2/20 0.47
FFAR1 O14842 1/20 0.47
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
NPC1 O15118 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
MCL1 Q07820 1/20 0.41
TRPV3 Q8NET8 1/20 0.40
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1711905 0.91 PIM1 (0.53) DHODHFFAR4FFAR1PIM1PIM3
SCHEMBL11906668 0.86 PRKAB2 (0.44) DHODHFFAR1PIM1PIM3PIM2
SCHEMBL11909249 0.86 FFAR1 (0.47) FFAR4FFAR1NPC1MEN1KMT2A
SCHEMBL11906508 0.84 TRPV3 (0.54) DHODHFFAR4PIM1PIM3PIM2
SCHEMBL11907358 0.82 FFAR4 (0.46) DHODHFFAR4FFAR1MEN1KMT2A
SCHEMBL11906876 0.80 CTSA (0.40) DHODHPIM1PIM3PIM2
SCHEMBL11908359 0.77 PDE2A (0.40) PIM1PIM3PIM2
SCHEMBL11907553 0.76 FGFR2 (0.41) DHODHPIM1PIM3PIM2NPC1
SCHEMBL1711786 0.76 GRK6 (0.47) DHODHFFAR1NPC1TRPV3KDM4E
SCHEMBL11907804 0.75 ALDH1A1 (0.42) PIM1PIM3PIM2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 DHODH 3326/4885FFAR4 3898/4885FFAR1 3373/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 DHODH 3326/4885FFAR4 3898/4885FFAR1 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.